Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis

References

• Compston JE, McClung M, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364–376. doi: 10.1016/S0140-6736(18)32112-3
   PubMed Web of Science ®Google Scholar
• Unnanuntana A, Gladnick BP, Donnelly E, et al. The assessment of fracture risk. J Bone Joint Surg Am. 2010;92(3):743–753. doi: 10.2106/JBJS.I.00919
   PubMed Web of Science ®Google Scholar
• Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011;377(9773):1276–1287. doi: 10.1016/S0140-6736(10)62349-5
   PubMed Web of Science ®Google Scholar
• Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353(9156):878–882. doi: 10.1016/S0140-6736(98)09075-8
   PubMed Web of Science ®Google Scholar
• Si L, Winzenberg TM, Jiang Q, et al. Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int. 2015;26(7):1929–1937. doi: 10.1007/s00198-015-3093-2
   PubMed Web of Science ®Google Scholar
• Eastell R, O’Neill TW, Hofbauer LC, et al. Postmenopausal osteoporosis. Nat Rev Dis Primers. 2016;2(1):16069. doi: 10.1038/nrdp.2016.69
   PubMedGoogle Scholar
• Shen Y, Huang X, Wu J, et al. The global burden of osteoporosis, low bone mass, and its related fracture in 204 countries and territories, 1990-2019. Front Endocrinol. 2022;13:882241. doi: 10.3389/fendo.2022.882241
   PubMed Web of Science ®Google Scholar
• Wang L, Yu W, Yin X, et al. Prevalence of osteoporosis and fracture in China: the China osteoporosis prevalence study. JAMA Netw Open. 2021;4(8):e2121106. doi: 10.1001/jamanetworkopen.2021.21106
   PubMed Web of Science ®Google Scholar
• Black DM, Rosen CJ, Solomon CG. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–262. doi: 10.1056/NEJMcp1513724
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765. doi: 10.1056/NEJMoa0809493
   PubMed Web of Science ®Google Scholar
• Zhang H, Gu JM, Chao AJ, et al. A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk. Acta Pharmacol Sin. 2023;44(2):446–453. doi: 10.1038/s41401-022-00954-y
   PubMed Web of Science ®Google Scholar
• Gu J, Zhang H, Xue Q, et al. Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: a randomized, double-blind, placebo-controlled, multicenter phase III study. J Orthop Translat. 2023;38:117–125. doi: 10.1016/j.jot.2022.06.007
   PubMed Web of Science ®Google Scholar
• Guo Y, Guo T, Di Y, et al. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial. Expert Opin Biol Ther. 2023;23(8):705–715. doi: 10.1080/14712598.2023.2178298
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–523. doi: 10.1016/S2213-8587(17)30138-9
   PubMed Web of Science ®Google Scholar
• Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599–2607. doi: 10.1210/jc.2013-4175
   PubMed Web of Science ®Google Scholar
• Denosumab china phase 3 study results. [cited 2023 Mar 2]. Available from: https://classic.clinicaltrials.gov/ct2/show/results/NCT02014467
   Google Scholar
• Jamshidi A, Vojdanian M, Soroush M, et al. Efficacy and safety of the biosimilar denosumab candidate (arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial. Arthritis Res Ther. 2022;24(1):161. doi: 10.1186/s13075-022-02840-8
   PubMed Web of Science ®Google Scholar
• Singh I, Jose V, Patel R, et al. Denosumab biosimilar in postmenopausal osteoporotic women: a randomized, assessor-blind, active-controlled clinical trial. Indian J Pharmacol. 2021;53(1):6–12. doi: 10.4103/ijp.IJP_346_19
   PubMed Web of Science ®Google Scholar
• Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res. 2000;15(7):1398–1404. doi: 10.1359/jbmr.2000.15.7.1398
   PubMed Web of Science ®Google Scholar
• Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391–420. doi: 10.1007/s00198-010-1501-1
   PubMed Web of Science ®Google Scholar
• Sugimoto T, Matsumoto T, Hosoi T, et al. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the denosumab fracture intervention randomized placebo controlled trial (DIRECT). Osteoporos Int. 2015;26(2):765–774. doi: 10.1007/s00198-014-2964-2
   PubMed Web of Science ®Google Scholar
• Ostrovsky V, Malnick S, Ish-Shalom S, et al. Denosumab-induced immune hepatitis. Biomedicines. 2021;9(1):76. doi: 10.3390/biomedicines9010076
   PubMed Web of Science ®Google Scholar
• Malnick S, Maor Y, Melzer E, et al. Severe hepatocytotoxicity linked to denosumab. Eur Rev Med Pharmacol Sci. 2017;21(1 Suppl):78–85.
   PubMedGoogle Scholar
• Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291–1296. doi: 10.1002/jbmr.3110
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190–198. doi: 10.1002/jbmr.3337
   PubMed Web of Science ®Google Scholar